title: [Guidelines on biologic drugs for the treatment of children with juvenile idiopathic arthritis (JIA)].
abstract: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children, and one of the major causes of short-term or long-term disability, and impairment of quality of life in childhood. Without early and adequate treatment the disease will progress and result with irreparable joint damage. The choice of therapy depends on the JIA subtype, disease activity index, prognostic factors, and prooven efficacy and probable side-effects of the drugs. The goal of modern JIA therapy is the achievement of complete disease remission, and not only the improvement of symptoms and temporarily inflammation control. The implementation of biologics significantly altered therapeutic approach to children with resistant JIA. We present Croatian guidelines on biologic drugs for the treatment of patients with JIA.
authors.affiliation: Reumatoloski odjel, Djeija bolnica Srebrnjak, Zagreb. lanabukovac@gmail.com
authors.forename: Lana Tambić
authors.initials: LT
authors.lastname: Bukovac
authors.forename: Mandica
authors.initials: M
authors.lastname: Vidović
authors.forename: Lovro
authors.initials: L
authors.lastname: Lamot
authors.forename: Marija
authors.initials: M
authors.lastname: Perica
authors.forename: Miroslav
authors.initials: M
authors.lastname: Harjacek
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D001688:Biological Products / Q000627:therapeutic use*; D002648:Child; D006801:Humans; D012074:Remission Induction
chemical_list: D018501:Antirheumatic Agents; D001688:Biological Products